54 results about "SGLT2 Inhibitor" patented technology

The disclosure provides methods of treating chronic kidney disease (CKD) and hypertension in a patient in need thereof, the method comprising administering to the patient a combination comprising baxdrostat or a pharmaceutically acceptable salt thereof and a sodium-glucose co-transporter 2 (SGLT2) inhibitor.

The invention discloses a preparation method of an SGLT2 inhibitor key intermediate, and belongs to the technical field of medicinal chemistry. The preparation method comprises the following steps: 1) reacting a compound B with trimethylchlorosilane under an alkaline condition to generate a compound C; 2) reacting the compound C with an aldehyde group reagent on an aromatic ring to generate a compound D; 3) reacting the compound E with a bromination reagent to generate a compound F; 4) preparing the compound F into a Grignard reagent to generate a compound G; 5) carrying out addition reaction on the compound D and a compound G to generate a compound H; and 6) carrying out dehydroxylation and trimethylsilyl protection on the compound H to generate a compound A. According to the preparation method, the risk caused by amplification of the Sandmeyer reaction in the original route is avoided, and meanwhile, the preparation cost of the key intermediate is greatly reduced.

One or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof are provided for use in the treatment and / or prevention of a metabolic disorder of an equine animal. For example, the treatment and / or prevention can be for laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and / or Equine Metabolic Syndrome in an equine animal.

There is provided herein a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, for use in the treatment and / or prophylaxis of hyperglycaemia or a disorder characterized by hyperglycaemia, wherein the treatment and / or prophylaxis further comprises administration of an SGLT2 inhibitor.

The present application relates to a kind of SGLT2 inhibitor in the preparation for treating hormone receptor low reaction type reproductive system disease in the application of drug, in particular, SGLT2 inhibitor and hormone can improve or enhance the sensitivity and / or for reversing the drug resistance of endocrine therapy drug, such as hormone, can enhance the therapeutic effect of such drug, especially in drug-resistant reproductive system disease and tumor treatment has good application prospect.

The present invention relates to combination of one or more SGLT2 inhibitors or pharmaceutically acceptable forms and / or salts thereof and one or more dopamine receptor agonists or pharmaceutically acceptable forms and / or salts thereof, preferably in the treatment and / or prevention of a metabolic disorder of an equine animal, wherein more preferably the metabolic disorder is one or more disorders selected from Equine Metabolic Syndrome (EMS), Equine Pituitary Pars Intermedia Dysfunction (PPID), also known as equine Cushing's syndrome, laminitis, vascular dysfunction, hypertension, hepatic lipidosis, hyperadrenocorticism, glucose intolerance, insulin resistance, hyperinsulinaemia, hirsutism, hyperhidrosis, polyuria, polydipsia, chronic infections, abnormal fat distribution, muscle wasting, abnormal weight loss and / or loss of appetite.

The present invention consists of a digital, always-online computer system designed to optimize perioperative safety through the automated integration of clinical and laboratory parameters. Unlike conventional medical calculators, this system implements a reactive logic engine that simultaneously calculates glomerular filtration rate (CKD-EPI 2021) and scores multiple risk scales (Goldman, LEE, ASA, CHA2DS2-VASc, HAS-BLED) without duplicate data entry. The system includes a drug reconciliation algorithm that cross-references the bleeding risk of the surgical procedure with the patient's renal function, generating accurate recommendations for discontinuing or continuing high-risk medications (anticoagulants, antiplatelet agents, SGLT2 inhibitors) based on current clinical evidence.

The present invention relates to one or more SGLT2 inhibitors or pharmaceutically acceptable forms thereof for use in the treatment and / or prevention of a metabolic disorder of an equine animal. In particular, the present invention relates to one or more SGLT2 inhibitors or a pharmaceutically acceptable form thereof for use in the treatment and / or prevention of laminitis, vascular dysfunction, hypertension, hepatic lipidosis, atherosclerosis, hyperadrenocorticism, Pituitary Pars Intermedia Dysfunction and / or Equine Metabolic Syndrome in an equine animal.

Methods of treating type 1 diabetes, improving cardiovascular health, delaying renal function decline, reducing the risk of cardiovascular death and reducing the risk of heart failure hospitalization, while minimizing adverse events such as diabetic ketoacidosis and severe hypoglycemia, using sodium-glucose cotransporter 2 (SGLT2) inhibitors are disclosed. In a preferred method, the SGLT2 inhibitor is sofogliflozin. Also disclosed are prescriptions for developing sofogliflozin and methods of administering sofogliflozin.

The present invention relates to a pharmaceutical combination, comprising (a) a pharmaceutical formulation comprising (i) lixisenatide or / and a pharmaceutically acceptable salt thereof, and (ii) insulin glargine or / and a pharmaceutically acceptable salt thereof, and (b) an SGLT2 inhibitor, or / and a pharmaceutically acceptable salt thereof.

The present disclosure relates to methods of treating patients with chronic kidney disease (CKD) with or without type 2 diabetes using an SGLT2 inhibitor such as dapagliflozin.

An object of the present invention is to improve the treatment and / or prevention of cardiovascular and renal diseases compared to already known monotherapies. A further object of the present invention is to provide a combination of pharmaceutical active ingredients for treating cardiovascular diseases, particularly cardiac and renal failure, characterized by chronic sodium retention, which reduces patient mortality and / or morbidity. Another object of the present invention is to improve the treatment and / or prevention of cardiovascular and renal diseases by administering a combination comprising finerenone and an SGLT2 inhibitor. [Solution] The present invention relates to pharmaceutical compositions and combinations comprising finerenone or its hydrate, solvate, or pharmaceutically acceptable salt or polymorph thereof, and an SGLT2 inhibitor or its hydrate, solvate, or pharmaceutically acceptable salt or polymorph thereof. The combinations can be used for the treatment and / or prevention of cardiovascular and / or renal diseases in humans and other mammals.

The invention discloses a pharmaceutical composition of an SGLT2 inhibitor and menthol and application of the pharmaceutical composition in preparation of drugs for preventing, improving and / or treating heart diseases. The pharmaceutical composition has a myocardial cell protection effect, can synergistically reduce intracellular calcium ion concentration and synergistically promote fatty acid metabolism, has advantages compared with single medication, and can be used for preparing drugs for treating, improving and / or preventing heart failure, coronary heart disease, myocardial infarction, hypertensive heart disease and the like.

A pharmaceutical composition comprising: (a) one or more of a first pellet comprising i. a first core, and ii. a first coating on the first core, wherein the first coating comprises a mineralocorticoid receptor (MR) modulator and a first binder; and (b) one or more of a second pellet comprising i. a second core, and ii. a second coating on the second core, wherein the second coating comprises an SGLT2 inhibitor, wherein the SGLT2 inhibitor is about 5% to about 20% by weight of the second pellet, wherein the composition comprises about 20% to about 50% by weight of the mineralocorticoid receptor (MR) modulator; and about 1% to about 10% by weight of the SGLT2 inhibitor. Said compositions for use in the treatment of chronic kidney disease or heart failure.

There is provided herein a β2-adrenergic receptor agonist, or a pharmaceutically acceptable salt thereof, for use in the treatment and / or prophylaxis of hyperglycaemia or a disorder characterized by hyperglycaemia, wherein the treatment and / or prophylaxis further comprises administration of an SGLT2 inhibitor.

Provided herein are compositions and methods for treating and preventing kidney disease. In particular, provided herein are methods of treating and preventing kidney disease with SGLT2 inhibitors in a subject with low levels of urinary EGF.

A combinational medicine of: esaxerenone or a pharmaceutically acceptable salt thereof; and a SGLT2 inhibitor.

Provided herein are pharmaceutical compositions useful for the treatment of diabetes and related conditions, diseases, and disorders. The present invention relates to compositions comprising a) a dipeptidyl peptidase IV (DPP IV) inhibitor, such as sitagliptin, b) a subtype 2 sodium-glucose transport (SGLT2) inhibitor, such as dapagliflozin or empagliflozin, and c) a biguanide, such as metformin. The DPP IV inhibitor, SGLT2 inhibitor, and biguanide are in a dose of about 20-75% of a minimum diabetes therapeutic dose.

Provided herein is a pharmaceutical composition comprising obicetrapib, or a pharmaceutically acceptable salt thereof, and an SGLT2 inhibitor, or a pharmaceutically acceptable salt thereof. Also provided is a dosage form comprising said pharmaceutical composition. In some embodiments, the dosage form is a solid dosage form, such as a tablet. Also provided is a process for preparing a fixed dose formulation of obicetrapib and an SGTL2 inhibitor, as well as a method for using said fixed dose formulation in the treatment of metabolic disorders (e.g., type 2 diabetes). Also provided is a method for treating or preventing metabolic disorders in a subject having or at risk of developing a metabolic disorder, comprising administering a therapeutically effective amount of obicetrapib, or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of at least one SGLT2 inhibitor, or a pharmaceutically acceptable salt thereof.

The present invention relates to pharmaceutical compositions of linagliptin, pharmaceutical dosage forms, their preparation, their use and methods for treating metabolic disorders.

Disclosed herein are compositions and methods for transdermal formulations of antidiabetic agents. An example transdermal formulation contains a SGLT2 inhibitor, and is used for the treatment of Type 2 diabetes.

The present invention provides a method for treating a subject with chronic kidney disease (CKD) or CKD and hypertension, the method comprising administering to the subject once daily a certain amount of lorenstat or a pharmaceutically acceptable salt thereof, said amount being effective in treating the subject's CKD or CKD and hypertension.

Provided herein is a pharmaceutical composition comprising obicetrapib, or a pharmaceutically acceptable salt thereof, and an SGTL2 inhibitor, or a pharmaceutically acceptable salt thereof. Also provided are dosage forms including the same. In some embodiments, the dosage form is a solid dosage form, such as a tablet. Also provided are processes for the preparation of fixed dose formulations of obicetrapib and an SGTL2 inhibitor, and methods for using the same in the treatment of a metabolic disorder (e.g., type 2 diabetes). Also provided are methods of treating or preventing a metabolic disorder in a subject who has or is at risk of developing a metabolic disorder, comprising: administering a therapeutically effective amount of obicetrapib, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of at least one SGLT2 inhibitor, or a pharmaceutically acceptable salt thereof.

The present invention describes synergistic compositions and combinations comprising one or more prolyl hydroxylase inhibitors or pharmaceutically acceptable salts thereof and a SGLT2 inhibitors or pharmaceutically acceptable salts thereof for the treatment of diabetes and diabetes induced CKD and the associated symptoms like anemia. Specifically, the present invention provides synergistic composition and combination of compound of formula (Ia) or its pharmaceutically acceptable salts and a SGLT2 inhibitors or pharmaceutically acceptable salts thereof for the treatment of diabetes and diabetes induced CKD and the associated symptoms like anemia. The present invention also describes the preparation of such compositions and combinations.

The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.

A pharmaceutical composition containing an SGLT2 inhibitor and menthol is effective for preventing, ameliorating, and / or treating heart diseases. The pharmaceutical composition has a myocardial cell protection effect, synergistically reduces intracellular calcium ion concentration, synergistically promotes fatty acid metabolism, has advantages compared with a single medication. The composition can be used for preparing medicines for treating, ameliorating, and / or preventing heart failure, coronary heart disease, myocardial infarction, hypertension heart disease, etc.

The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.

To provide a novel agent having an action of promoting urinary excretion of sugar.SOLUTION: Provided is an agent for promoting urinary excretion of sugar, the agent containing Dai-saiko-to or Bofu-tsusho-san. Also provided is an agent for promoting urinary excretion of sugar, the agent containing Dai-saiko-to and being used so as to be taken before meals. Also provided is an agent for promoting urinary excretion of sugar, the agent containing Bofu-tsusho-san and being used so as to be taken before meals. Further provided is an SGLT2 inhibitor that contains Dai-saiko-to or Bofu-tsusho-san.SELECTED DRAWING: Figure 3